Platelet glycoprotein IIIa (platelet antigen 1/platelet antigen 2) polymorphism and 1-year outcome in patients with stable coronary artery disease

Blood Coagulation and Fibrinolysis

Volumn 21, Issue 7, 2010, Pages 674-678

  Addad, Faouzi ^a   Elalamy, Ismail ^b   Chakroun, Tahar ^c   Abderrazek, Fatma ^a   Dridi, Zohra ^a   Hamdi, Sonia ^a   Hassine, Mohssen ^a,d   Ben Farhat, Mohamed ^a   Gerotziafas, Grigoris ^b   Hatmi, Mohamed ^b   Gamra, Habib ^a  

^a FATTOUMA BOURGUIBA UNIVERSITY HOSPITAL   (Tunisia)

^b SORBONNE UNIVERSITÉ   (France)

^c FARHAT HACHED HOSPITAL   (Tunisia)

^d INSTITUT PASTEUR   (France)

Author keywords

cardiac events; coronary artery disease; platelet glycoprotein IIIa; platelet PLA1 PLA2 polymorphism

Indexed keywords

ACETYLSALICYLIC ACID; GLYCOPROTEIN IIIA; PLATELET ANTIGEN 1; PLATELET ANTIGEN 2; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CARDIOVASCULAR RISK; CORONARY ARTERY DISEASE; DISEASE ASSOCIATION; DNA POLYMORPHISM; FEMALE; FOLLOW UP; GENOTYPE; HEART DEATH; HEART EJECTION FRACTION; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HOMOZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; POLYMERASE CHAIN REACTION; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; RECURRENT DISEASE; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; STROKE; THROMBOSIS PREVENTION; TREATMENT OUTCOME; UNSTABLE ANGINA PECTORIS;

AGE FACTORS; AGED; ASPIRIN; CORONARY ARTERY DISEASE; ENDPOINT DETERMINATION; FEMALE; GENOTYPE; HUMANS; INTEGRIN BETA3; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; PROGNOSIS; PROSPECTIVE STUDIES; RISK FACTORS; STROKE VOLUME; TREATMENT OUTCOME;

EID: 77958169963     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/MBC.0b013e32833e47c1     Document Type: Article

References (32)

1. Davi G, Patrono C. Platelet activation and atherothrombosis. N Engl J Med 2007; 357:2482-2494.
2. Lefkovits J, Plow EF, Topol EJ. Platelet glycoprotein IIb/IIIa receptors in cardiovascular medecine. N Engl J Med 1995; 332:1553-1559.
3. Kunicki TJ, Newman PJ. The molecular immunology of human platelet proteins. Blood 1992; 80:1386-1404.
4. Newman PJ, Derbes RS, Aster RH. The humain platelet alloantigen, PlA1 and PlA2 are associated with leucine 33 to praline aminoacid polymorphism in membrane glycoprotein IIIa, and are distinguishable by DNA typing. J Clin Invest 1989; 83:1778-1781.
5. Weiss EJ, Bray PF, Tayback M, Schulman SP, Kickler TS, Becker LC, et al. A polymorphism of platelet glycoprotein receptor as an inherited risk factor for coronary thrombosis. N Engl J Med 1996; 334:1090-1094. (Pubitemid 26120186)
6. Ridker PM, Hennekens CH, Schmitz C, Stampfer MJ, Lindpaintner K. PlA1/ A2 polymorphism of platelet glycoprotein IIIa and risks of myocardial infarction, stroke, and venous thrombosis. Lancet 1997; 349:385-388. (Pubitemid 27077666)
7. Herrman SM, Poirier O, Marques-vidal P, Evans A, Arveiler D, Luc G, et al. The Leu33/Pro polymorphism (PlA1/PlA2) of the glycoprotein IIIa (GPIIIa) receptor is not related to myocardial infarction in the ECTIM study. Etude Cas-Temoins de l'Infarctus du Myocarde. Thromb Haemost 1997; 77:1179-1181. (Pubitemid 27311991)
8. Anderson JL, King GJ, Bair TL, Elmer SP, Muhlestein JB, Habashi J, et al. Association between a polymorphism in the gene encoding glycoprotein IIIa and myocardial infarction or coronary artery disease. J Am Coll Cardiol 1999; 33:727-733.
9. Bottiger C, Kastrati A, Koch W, Mehilli J, Seidl H, Schomig K, et al. HPA-1 and HPA-3 polymorphisms of the platelet fibrinogen receptor and coronary artery disease and myocardial infarction. Thromb Haemost 2000; 83:559-562. (Pubitemid 30201131)
10. Bojesen SE, Juul K, Schnohr P, Tybjaerg-Hansen A, Nordestgaard BG. Platelet glycoprotein IIb/IIIa PlA2/PlA2 homozygosity associated with risk of ischemic cardiovascular disease and myocardial infarction in yong men, the Copenhagen City Heart Study. J Am Coll Cardiol 2003; 42:661-667. (Pubitemid 37000182)
11. Cannon CP, Battler A, Brindis RG, Cox JL, Ellis SG, Every NR, et al. American College of Cardiology key data elements and definitions for measuring the clinical management and outcomes of patients with acute coronary syndromes: a report of the American College of Cardiology task force on clinical data standards (acute coronary syndromes writing committee). J Am Coll Cardiol 2001; 38:2114-2130. (Pubitemid 33116592)
12. Mojaat N, Halle L, Proulle V, Hmida S, Ben Hamed L, Boukef K, et al. Gene frequencies of human platelet antigens in the Tunisian population. Tissus Antigens 1999; 54:201-204. (Pubitemid 29410781)
13. Mamotte CD, van Bockxmeer FM, Taylor RR. PlA1/A2 polymorphism of glycoprotein IIIa and risk of coronary artery disease and restenosis following coronary angioplasty. Am J Cardiol 1998; 82:13-16.
14. Kastrati A, Koch W, Gawaz M, Mehilli J, Bö ttiger C, Schö mig K, et al. PlA polymorphism of glycoprotein IIIa and risk for adverse events after coronary stent placement. J Am Coll Cardiol 2000; 36:84-89. (Pubitemid 30466116)
15. Bray PF, Cannon CP, Goldschmidt-Clermont P, Moyé LA, Pfeffer MA, Sacks FM, et al. The platelet PlA2 and angiotensin-converting enzyme (ACE) D allele polymorphisms and risk of recurrent events after acute myocardial infarction. Am J Cardiol 2001; 88:347-352. (Pubitemid 32823293)
16. Le Hello C, Morello R, Lequerrec A, Duarte C, Riddell J, Hamon M. Effect of PlA1/PlA2 glycoprotein IIIa gene polymorphism on the long-term outcome after successful coronary stenting. Thromb J 2007; 5:19.
17. Di Castenuovo A, De Gaetano G, Donatio MB. Platelet glycoprotein receptor IIIa polymorphism PlA1/PlA2 and coronary risk: a meta-analysis. Thromb Haemost 2001; 85:626-633. (Pubitemid 32293697)
18. Burr D, Doss H, Cooke GE, Goldschmidt-Clemont PJ. A meta-analysis of studies on the association of platelet PLA polymorphism of glycoprotein IIIa and risk of coronary heart study. Stat Med 2003; 22:1741-1760. (Pubitemid 36575612)
19. Feng D, Lindpaintner K, Larson MG, Rao VS, O'Donnell CJ, Lipinska I, et al. Increased platelet aggregability associated with platelet GPIIIa PlA2 polymorphism: the Framingham Offspring Study. Arterioscler Thromb Vasc Biol 1999; 19:1142-1147. (Pubitemid 29177367)
20. Michelson AD, Furman MI, Goldschmidt-Clermont P, Mascelli MA, Hendrix C, Coleman L, et al. Platelet GP IIIa Pl(A) polymorphisms display different sensitivities to agonists. Circulation 2000; 101:1013-1018. (Pubitemid 30131704)
21. Kozieradzka A, Kamiń ski KA, Pepiń ski W, Janica J, Korecki J, Skolimowski K, et al. The effect of glycoprotein IIIa A1/A2 gene polymorphism on oneyear outcome in patients with ST-segment elevation myocardial infraction treated with primary percutaneous coronary intervention. Kardiol Pol 2006; 64:1350-1355. (Pubitemid 46011613)
22. Gruchäa M, Cieć wierz D, Ochman K, Targoń ski R, Dubaniewicz W, Sobiczewski W, et al. Association between the PlA platelet glycoprotein GPIIIa polymorphism and extent of coronary artery disease. Int J Cardiol 2003; 88:229-237. (Pubitemid 36513661)
23. Michelsson J, Perola M, PenttiläA, Goldschmidt-Clermont PJ, Karhunen PJ. The GPIIIa (b3 integrin) PlA polymorphism in the early development of coronary atherosclerosis. Atherosclerosis 2001; 154:721-727.
24. Andrioli G, Minuz P, Solero P, Pincelli S, Ortolani R, Lussignoli S, et al. defective platelet response to arachidonic acid and thromboxane A2 in subjects with PlA2 polymorphism of b3 subunit (glycoprotein IIIa). Br J Haematol 2000; 110:911-918.
25. Lasne D, Krenn M, Pingault V, Arnaud E, Fiessinger JN, Aiach M, et al. Interdonor variability of platelet response to thrombin receptor activation: influence of PlA2 polymorphism. Br J Haematol 1997; 99:801-807. (Pubitemid 28047142)
26. Macchi L, Christiaens L, Brabant S, Sorel N, Ragot S, Allal J, et al. Resistance in vitro to low-dose aspirin is associated with platelet Pl (GP IIIa) polymorphism but not with C807T (GP Ia/I1a) and C-5T Kozak (GP Iba) polymorphism. J Am Coll Cardiol 2003; 42:1115-1119. (Pubitemid 37108603)
27. Lopes NM, Pereira AC, Hueb W, Soares PR, Lanz JR, Gersh BJ, et al. Effect of glycoprotein IIIa PlA2 polymorphism on outcome of patients with stable coronary artery disease and effect of smoking. Am J Cardiol 2004; 93:1469-1472. (Pubitemid 38749201)
28. Senti M, Aubo C, Bosch M, Pavesi M, Pena A, Masia R, et al. Platelt glycoprotein IIb/IIIa genetic polymorphism is associated with plasma fibrinogen levels in myocardial infarction patients. Clin Biochem 1998; 31:647-651. (Pubitemid 29021475)
29. Goodman T, Sharma P, Ferro A. The genetics of aspirin resistance. Int J Clin Pract 2007; 61:826-834. (Pubitemid 46587879)
30. Wheeler GL, Braden GA, Bray PF, Marciniak SJ, Mascelli MA, Sane DC. Reduced inhibition by abciximab in platelets with the PlA2 polymorphism. Am Heart J 2002; 143:76-82.
31. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, Ramírez C, Escaned J, Moreno R, et al. PlA polymorphism and platelet reactivity following clopidogrel loading dose in patients undergoing coronary stent implantation. Blood Coagul Fibrinolysis 2004; 15:89-93. (Pubitemid 38534691)
32. Syros G, Mehran R, Weisz G, Kittas C, Moses JW, Leon L, et al. Role of PlA2 polymorphism on clinical events after percutaneous coronary intervention. Acute Card Care 2009; 11:88-91.